FDA approves first targeted therapy for bladder cancer
On April 12, the FDA approved Balversa (erdafitinib) for adult patients with locally advanced or metastatic bladder cancer that has a susceptible genetic alteration…
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.